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Abstract
Background: Cutaneous Malignant Melanoma causes over 75% of skin cancer-related deaths, and
it is clear that many factors may contribute to the outcome. Matrix Metalloproteinases (MMPs) play
an important role in the degradation and remodeling of the extracellular matrix and basement
membrane that, in turn, modulate cell division, migration and angiogenesis. Some polymorphisms
are known to influence gene expression, protein activity, stability, and interactions, and they were
shown to be associated with certain tumor phenotypes and cancer risk.
Methods:  We tested seven polymorphisms within the MMP-9  gene in 1002 patients with
melanoma in order to evaluate germline genetic variants and their association with progression and
known risk factors of melanoma. The polymorphisms were selected based on previously published
reports and their known or potential functional relevance using in-silico methods. Germline DNA
was then genotyped using pyrosequencing, melting temperature profiles, heteroduplex analysis, and
fragment size analysis.
Results: We found that reference alleles were present in higher frequency in patients who tend
to sunburn, have family history of melanoma, higher melanoma stage, intransit metastasis and
desmoplastic melanomas among others. However, after adjustment for age, sex, phenotypic index,
moles, and freckles only Q279R, P574R and R668Q had significant associations with intransit
metastasis, propensity to tan/sunburn and primary melanoma site.
Conclusion: This study does not provide strong evidence for further investigation into the role
of the MMP-9 SNPs in melanoma progression.
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Background
Cutaneous Malignant Melanoma (CMM) causes over
75% of skin cancer-related deaths. Melanoma incidence
has been rising steadily, with 62,190 new cases and 7,910
deaths estimated for 2006 in the United States [1]. It is
becoming clear that genetic factors contribute to the
development and/or progression of the disease, as well as
the exposure to ultraviolet light (UV) and tumor microen-
vironment.
Invasive primary melanomas are aggressive and prone to
metastasis. Proteolytic degradation of the extracellular
matrix (ECM) constituents may release and activate ECM-
bound cytokines and ECM fragments (matrikines) that
modulate cell growth, migration and angiogenesis [2,3].
Under physiological conditions, matrix metalloprotein-
ase (MMP) expression is low in most cells; however, many
tumor types show a dramatically overexpression of these
enzymes. This, in turn, produces an overactive proteolysis
of the ECM and basement membrane, promoting cancer
invasion through a variety of biochemical, biophysical,
and signal transduction mechanisms.
Liu et al found that the MMP-2 and MMP-9 protein levels
were higher in breast tumor tissues when compared to the
corresponding normal tissue (p < 0.01) and that MMP-2
was significantly increased in larger tumors (p < 0.0001),
and in metastatic lesions (p < 0.05) [4]. MMP-9 expres-
sion was significantly higher in colorectal tumors when
compared to the adjacent normal tissue (p < 0.05) [5]. In
melanoma, there is some evidence suggesting a role of
MMPs in the progression of the disease. It has been dem-
onstrated that invasive melanoma cell lines show higher
MMP-9 expression and higher activity when compared to
non-invasive cell lines [6,7]. In primary melanomas,
MMP-9 is variably expressed in radial but not in the verti-
cal growth phase and the de novo expression seems associ-
ated with early invasion [8]. MMP-2 was evident by
immunohistochemistry in malignant melanoma lesions,
but not in benign and atypical nevi [9]. Corte et al found
an association between MMP-13 expression with mitotic
index (p = 0.002) in CMM [10]. Circulating blood levels
of MMP-9 may be useful in predicting progression in
patients with melanoma although it has been suggested
that serum levels contain higher levels of proteases
released during the clotting process, and therefore, the
results obtained by Nikkola et al should be validated using
plasma samples [11-14].
Some polymorphisms are known to influence gene
expression, protein activity, protein stability and protein-
protein interactions, and some of them are associated
with an increased risk for cancer and other diseases. To
date, and to the best of our knowledge, there are no
reports on associations between polymorphisms in MMP-
9 and melanoma.
Polymorphisms in the promoter of MMP-9 have been
implicated in the regulation of gene expression and sus-
ceptibility to various diseases. Two out of five identified
sequence variants are functionally relevant: a single nucle-
otide polymorphism at (-)1562 bp (C → T) and a (CA)n
microsatellite at position (-)131 bp. The C to T substitu-
tion at position (-)1562 results in a loss of binding of a
nuclear protein and an increase in transcriptional activity
in macrophages [15]. Similarly, the highest promoter
activity has been observed in reporter constructs contain-
ing 21 or 23 (CA) tandem repeats, suggesting that the
number of repeats modulates the transcriptional activity
[15].
To test the hypothesis that polymorphisms in the MMP-9
gene [GenBank: AF538844, OMIM: 120361] may influ-
ence melanoma progression, we examined seven different
polymorphisms in a cohort of 1002 patients with
melanoma in order to evaluate germline genetic variants
in the MMP-9 gene and their association with progression
and known risk factors of melanoma.
Methods
Study population
We recruited 1002 patients with melanoma (stages 0–IV)
at Memorial Sloan-Kettering Cancer Center (MSKCC),
New York, USA. The study protocol was approved by the
MSKCC Institutional Review Board (IRB). Ninety-six per-
cent of the patients approached signed an informed con-
sent and agreed to participate in the study. Patients filled
out a short self-administered questionnaire that included
information on gender, race, age, family history, freckling
density, hair and eye color, propensity to burn, and ability
to tan after sun exposure. The information on hair color,
eye color, and propensity to tan or sunburn were com-
bined into a single variable, the "phenotypic index" [16].
This index, with minimum and maximum values of 1 and
5, represents the sum of points assigned to the following
phenotypic features: hair color (1 if brown/black; 2 if light
brown/blond; 3 if red/auburn); eye color (0 if brown; 1 if
green/hazel/blue); and propensity to tan or sunburn (0 if
tend to tan; 1 if tend to sunburn). We also obtained clin-
icopathological information including presence of dys-
plastic nevi, multiple primary tumors, stage at diagnosis
and at follow-up (based on the AJCC 2002 classification),
disease status, disease progression, and survival among
others. The characteristics of the study group are shown in
Table 1.
Biospecimens
Blood was obtained from 17 patients and buccal cells
were collected from 985 individuals. DNA from buccalBMC Medical Genetics 2007, 8:10 http://www.biomedcentral.com/1471-2350/8/10
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Table 1: Clinico-pathological characteristics of the study group
Variable Patients %
Gender
Males 573 57.2
Females 429 42.8
Family History
Yes 167 16.7
No 826 82.4
Unknown 9 0.9
Multi-primary Melanoma
Yes 152 15.2
No 849 84.7
Unknown 1 0.1
Stage at Diagnosis
05 8 5 . 8
I 504 50.3
II 235 23.4
III 169 16.9
IV 9 0.9
Unstagable¥ 27 2.7
Current Stage
05 6 5 . 6
I 435 43.4
II 159 15.9
III 217 21.7
IV 129 12.9
Unstagable¥ 60 . 5
Primary Clark Level
I5 8 5 . 8
II 108 10.8
III 150 14.9
IV 489 48.8
V6 9 6 . 9
Unknown 128 12.8
Thickness (mm)
In situ 58 5.8
< 1.01 321 32.0
1.01 – 2.00 272 27.1
2.01 – 4.00 161 16.1
> 4.00 121 12.1
Unknown 69 6.9
Distant Metastasis
Yes 130 13.0
No 870 86.8
N/Aφ 20 . 2
Phenotypic Index
1 (low risk) 38 3.8
2 210 21.0
3 317 31.6
4 328 32.7
5 (high risk) 105 10.5
N/Aφ 40 . 4
Site of the Primary Melanoma
Extremities 535 53.4
Trunk 342 34.1
Head and Neck 71 7.1
Non-cutaneousω 12 1.2
Unknown 42 4.2
¥due to missing data on the "T" classification
φN/A: not available
ω90% mucosal melanomas and 10% other sites.BMC Medical Genetics 2007, 8:10 http://www.biomedcentral.com/1471-2350/8/10
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cells was extracted using Puregene® kits (Gentra Systems
Inc., Minneapolis, USA), and DNA from blood was
extracted with the QIAamp DNA Blood kit (QIAGEN Inc.
Valencia, USA) using manufacturer's recommendations.
DNA concentration was measured by spectrophotometry
at 260 nm in a Spectramax Plus 384 (Molecular Devices,
Sunnyvale, USA). The DNA quality was determined by the
ratio A260/A280.
Selection of SNPs
All known non-synonymous variations in MMP-9 availa-
ble in the dbSNP database of the National Center for Bio-
technology Information (NCBI) [17] were evaluated with
in-silico methods to determine which ones potentially dis-
turb the molecular structure and/or function of MMP-9.
In the analysis we determined: 1) the steric distortions
and hydrogen bond losses caused by the polymorphisms;
2) the effect of the residue changes on the interactions
with known ligands (metal cofactors, synthetic and natu-
ral inhibitors); and 3) the effect on conserved or specifi-
city residues of four superfamilies of MMP-9 domains
(MMP N-terminal domain, catalytic domain, fibronectin
type II domain, hemopexin domain) by multiple
sequence analysis [18].
Genotyping
All genotyping was done with PCR-based methods and
included: melting temperature analysis [19] coupled to
the LightTyper instrument (Roche Applied Science, Indi-
anapolis, USA), pyrosequencing [20] with the PSQ™ 96
MA or PSQ™HS 96A instruments (Biotage AB, Uppsala,
Sweden), fragment size analysis [21] by an ABI PRISM®
3100 Genetic Analyzer (Applied Biosystems, Foster City,
USA), and heteroduplex analysis [22,23] using the Wave
DNA Fragment Analysis System (Transgenomic, Omaha,
USA). The PCR primers and PCR conditions are listed in
the Additional file 1. For the heteroduplex analysis, each
sample was run unmixed and mixed with equimolar
amount of wild type control. The MMP-9 (-)1562 C/T was
assessed with a nested PCR because the largest fragment,
although specific, was not suitable for pyrosequencing
analysis. All genotyping included known internal controls
and were considered for the analysis when there was
100% agreement between 2 independent laboratory
members. Samples that failed were repeated once or twice,
as needed.
Sequencing
Samples were PCR amplified and then purified with a
purification kit following the manufacturer's recommen-
dations (QIAGEN Inc., Valencia, USA). One to 10 ng of
each purified sample were sequenced in the DNA
Sequencing Core Facility at Memorial Sloan-Kettering
Cancer Center. Samples were run in an ABI 3730-XLDNA
Analyzer (Applied Biosystems, Foster City, USA).
Sequencing electropherograms were read at least twice,
reviewed manually and with the Mutation Surveyor soft-
ware, version 2.41 (SoftGenetics LLC, State College, USA).
Statistical analysis
Two-sided Chi-Square tests, Cochran-Armitage tests for
trend [24], and Fisher's exact tests were performed at each
individual SNP in the MMP-9 gene to test for association
with various clinical and epidemiologic factors. Multivar-
iate analyses were conducted using logistic regression,
adjusting for age, sex, phenotypic index, moles and freck-
les. To investigate associations between SNP and overall
survival, time was measured from initial date of diagnosis
with melanoma to date of death or last follow-up. Poten-
tial associations between time to recurrence, defined as a
patient's first recurrence of melanoma, time to disease
progression, and genotype were also examined. Survival
estimates were computed using the methods of Kaplan
and Meier [25] and comparisons between genotypes were
made using the log-rank test. All statistical analyses were
carried out using SAS version 9.1 (SAS Institute, Cary,
NC). The EM algorithm [26] was used to estimate the hap-
lotype frequencies and corresponding standard errors and
confidence intervals were estimated using a jackknife
process. For dichotomous traits, likelihood ratio tests
were conducted to test for haplotype-trait association
[27]. For continuous traits, a generalized linear models
framework was utilized and score tests were constructed
[28]. Omnibus test statistics over all haplotypes in addi-
tion to tests for association between each individual hap-
lotype and the trait were performed. Exact p-values were
computed using 1000 permutations. Analyses were con-
ducted using SAS Genetics 9.1 software (SAS Institute Inc,
Cary, North Carolina) and haplo.stat in R version 2.1.1
(The R Foundation for Statistical Computing, Vienna,
Austria).
Results
We included 1002 patients with melanoma stages 0 (in
situ) to IV in the study. Ninety-five percent of these were
cutaneous malignant melanoma patients; the rest
included mucosal melanomas, other non-cutaneous sites,
or unknown primary sites. Ninety-six percent were Cauca-
sians followed by Hispanic (1.1%), black non-Hispanic
(1.1%), and Asian/Indian (0.3%); fifteen had missing
information on ethnicity and one refused to answer the
question about race (1.5%). The age at diagnosis ranged
from 5 to 89 years old (mean = 54 and median = 55).
Evaluation of non-synonymous SNPs
There are 10 non-synonymous MMP-9 variations in the
dbSNP (build 123). These variations are located in the
activation peptide domain (A20V, E82K), catalytic
domain (N127K, D165N, L447P, L449P), fibronectin
type II domain (R279Q), and hemopexin domainBMC Medical Genetics 2007, 8:10 http://www.biomedcentral.com/1471-2350/8/10
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(P574R, R621K, R668Q). Currently, there is no complete
3D structure of MMP-9 in any known biologically impor-
tant state (precursor, active, bound to TIMP inhibitor).
However, there are 3D structures of different fragments of
MMP-9 and its homologs, including the complexes with
TIMPs.
Therefore, we derived a synthetic structure of MMP-9 by
3D superposition of different structural fragments of
MMP-9 and its close homolog MMP-2. Although this syn-
thetic structure was not optimized for residue-residue
contacts, it showed the MMP-9/TIMP binding site. Struc-
ture-based analysis of residue-residue interactions and
analysis of protein domain family alignments suggested
that five of the 10 non-synonymous SNPs -N127K,
D165N, R279Q, P574R, and R668Q- would be appropri-
ate candidates that might affect MMP-9 function and/or
interaction with its inhibitors. None of the 5 polymorphic
residues studied localizes to the MMP-9/TIMP binding
interface (Figure 1), however all of these residues have
specific interactions between their side-chain and sur-
rounding residues, which are abolished as a result of an
amino acid change. Our analysis is consistent with the
results obtained by PolyPhen (Polymorphism Phenotyp-
ing [29]).
Genotyping and statistical analysis
We genotyped one microsatellite and one SNP in the pro-
moter of MMP-9 and five coding SNPs. The genotype and
allele distributions are summarized in Tables 2 and 3, and
were similar to those described in the dbSNP for Euro-
pean panels (HapMap-CEU, AFD EUR and PGA-Euro-
pean panels from dbSNP build 125) and previous
published data. Hardy-Weinberg equilibrium was
observed for all the polymorphisms.
Statistically significant differences (p < 0.05) in genotype
frequencies were observed in eleven different melanoma
phenotypic groups. However, when we adjusted for age,
sex, phenotypic index, moles, and freckles only four asso-
ciations remained significant. The complete set of results
is available as additional data (see Additional files 2, 3
and 4).
Promoter (-)131 (CA)n
The distribution of alleles for the microsatellite showed a
bimodal distribution with a first high-frequency peak at
14 repeats (0.519) and a second low-frequency group of
peaks with 21 and higher number of repeats (0.162,
0.135, and 0.081 for 21, 22, and 23 repeats respectively).
Published data are contradictory with regard to the corre-
lation between different promoter activity and different
promoter lengths [30-32]. Therefore, we conducted the
statistical analysis in two different ways. In the first analy-
sis, we grouped the samples according to the presence of
(CA)14 and in the second according to the presence of
(CA)≥ 21 alleles (1 or 2 alleles vs none for both cases). No
significant associations were found after adjustment for
age, sex, phenotypic index, moles and freckles.
Promoter (-)1562 C/T
This polymorphism did not show any significant associa-
tion with melanoma.
N127K and D165N
These polymorphisms showed no variation in our study
group.
Q279R
The QQ genotype appeared more frequently in patients
with intransit metastasis (p = 0.03, padjusted = 0.02; Table
4). The same genotype was also more frequent among
patients who tend to sunburn (p < 0.01, padjusted< 0.01;
Table 4).
P574R
This polymorphism was studied only in a subset of 538
specimens due to the low frequency of the minor allele
(0.046), However, the R allele was more frequent among
patients with melanomas in the extremities (p = 0.01, pad-
justed = 0.02; Table 4).
Localization of studied SNPs on a model structure of MMP9 Figure 1
Localization of studied SNPs on a model structure of 
MMP9. The MMP-9 variations studied -N127K, D165N, 
Q279R, P574R, R668Q- are shown in context of MMP-9 3D 
structure. The reference residues have significant interac-
tions with surrounding residues; therefore, it is likely that 
variations in these amino acids might disturb the protein sta-
bility and function. Residues N127, D165 are located in the 
catalytic domain (blue), Q279 is in the fibronectin type II 
domain (blue), and P574 and R668 are located in the hemo-
pexin domain (green). The newly discovered variation F571V 
is shown in magenta. TIMP molecules, bound to the catalytic 
domain, are also depicted in the figure (red).BMC Medical Genetics 2007, 8:10 http://www.biomedcentral.com/1471-2350/8/10
Page 6 of 10
(page number not for citation purposes)
R668Q
The tendency to tan or sunburn was associated with the
668RR genotype, which is more frequent among patients
who tend to sunburn (p = 0.01, padjusted = 0.02; Table 4).
Significance was not reached when we looked at associa-
tions between any of the MMP-9 polymorphisms studied
and: tumor thickness, tumor infiltrating lymphocytes,
number of moles, presence of multiple primary
melanoma, lymphovascular invasion, perineural inva-
sion, tumor mitotic index, ulceration, regression, satel-
lites, and distant metastasis.
No associations were found when we performed the Kap-
lan-Meier analysis for progression, survival and recurrence
for all the polymorphisms (data not shown).
F571V
We found a previously unreported variation in codon 571
in one sample. The T to G change results in a mutation
from F to V (ss49785039). The bulky side-chain of F571
is tightly packed within the hydrophobic core of the
MMP-9 hemopexin domain. The substitution of the phe-
nylalanine to valine, a small hydrophobic residue, should
not result in steric clashes, destruction of the hydrophobic
core or destabilization of beta-strand structure; therefore
we evaluate this mutation as a benign change. Conversely,
PolyPhen ranked this mutation as "probably damaging".
Haplotype analysis
The haplotype analysis was performed with the following
polymorphisms: promoter (-)1562 C/T, promoter (-)131
(CA)n, Q279R and R668Q. The other SNPs were excluded
because of their low or null heterozygosity.
The analysis revealed that the most frequent haplotype
contained all reference alleles and was (-)1562C-(CA)< 21-
279Q-668R with a frequency of 55.4%; followed by (-
)1562C-(CA)≥ 21-279R-668R (18.4%), and (-)1562T-
(CA)≥ 21-279R-668Q (12.6%). All other haplotypes
showed a frequency less than 9%. The Omnibus test
showed non-significant differences between clinical stage
at diagnosis, Clark level, tumor thickness, tumor site, and
phenotypic index, and the MMP-9 haplotypes (data not
shown).
Table 2: Frequency of the different SNP genotypes and alleles in the population studied
Minor Allele n* Polymorphism Reference ID Frequency (n*) Allele Frequency
< 5% 538 N127K (C > G) rs3918252 NN: 1.000 (538) N: 1.000
NK: 0.000 (0)
KK: 0.000 (0) K: 0.000
N/A: -- (0)
D165N (G > A) rs8125581 DD: 1.000 (537) D: 1.000
DN: 0.000 (0)
NN: 0.000 (0) N: 0.000
N/A: -- (1)
P574R (C > G) rs2250889 PP: 0.910 (485) P: 0.954
PR: 0.088 (47)
RR: 0.002 (1) R: 0.046
N/A: -- (5)
> 5% 1002 (-)1562 C > T rs3918242 CC: 0.721 (716) C: 0.852
CT: 0.262 (260)
TT: 0.017 (17) T: 0.148
N/A: -- (17)
Q279R (A > G) rs2664538 QQ: 0.420 (420) Q: 0.645
QR: 0.451 (451)
RR: 0.130 (130) R: 0.355
N/A: -- (1)
R668Q (G > A) rs2274756 RR: 0.718 (716) R: 0.850
RQ: 0.263 (262)
QQ: 0.019 (19) Q: 0.150
N/A: -- (5)
*Total number of patients genotyped; N/A: not available due to genotyping failuresBMC Medical Genetics 2007, 8:10 http://www.biomedcentral.com/1471-2350/8/10
Page 7 of 10
(page number not for citation purposes)
Discussion
There are several reports showing different MMP expres-
sion patterns in melanoma [6,33-35] but, to the best of
our knowledge, this is the first genetic study to examine
the role of polymorphisms in MMP-9 in melanoma pro-
gression and other melanoma risk factors. We hypothe-
sized that the MMP-9  polymorphisms might alter the
expression and activity of the enzyme, increasing ECM
degradation and invasion, leading to melanoma progres-
sion.
Gene transcription is the primary point of regulation of
MMPs; therefore, sequence changes in the promoter may
have important implications for the transcription, and in
turn, for the protein levels and cell physiology. This led us
to assess previously described functional polymorphisms
within the promoter region of MMP-9: (-)1562 C > T and
(-)131 (CA)n.
The polymorphism at position (-)1562 changes the pro-
moter activity of MMP-9 because the T allele abolishes a
Table 3: Microsatellite (-) 131 (CA)n allele frequencies
Number of (CA) repeats Frequency (n)
12 0.001 (1)
13 0.000 (0)
14 0.539 (1040)
15 0.017 (32)
16 0.001 (2)
17 0.001 (2)
18 0.000 (0)
19 0.018 (34)
20 0.017 (32)
21 0.169 (325)
22 0.140 (270)
23 0.084 (162)
24 0.015 (28)
N/A -- (76)
N/A: not available due to genotyping failures
Table 4: Statistically significant associations between the different SNPs and clinico-pathological variables
Genotype p-value
Q279R QQ (reference) QR + RR
Intransit Metastasis
Yes 17 (63%) 10 (37%)
No 384 (41%) 557 (59%) p = 0.03; p = 0.02¥
Tan/Burn Tendency
Tend to Tan 26 (29%) 65 (71%)
Tend to Sunburn 394 (43%) 516 (57%) p < 0.01; p < 0.01¥
P574R PP (reference) PR + RR
Site
Extremities 263 (88%) 36 (12%)
Trunk 164 (96%) 7 (4%)
Head & Neck 36 (97%) 1 (3%)
Non-cutaneous 6 (100%) 0 (0%) p = 0.01; p = 0.02¥
R668Q RR (reference) RQ + QQ
Tan/Burn Tendency
Tend to Tan 55 (60%) 36 (40%)
Tend to Sunburn 661 (73%) 245 (27%) p = 0.01; p = 0.02¥
¥ p-value adjusted for: age, sex, phenotypic index, moles, and frecklesBMC Medical Genetics 2007, 8:10 http://www.biomedcentral.com/1471-2350/8/10
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binding site for a transcription repressor [36]. Although
the less active C allele was expected to be present in less
aggressive lesions, we found the opposite results. A similar
association between this SNP and breast cancer was found
by Grieu et al, where the T allele correlated with non-duc-
tal histology, positive estrogen receptor and absence of
TP53 mutations in breast cancer [37]. However, Mat-
sumura et al found significant associations between this
allele and the invasive phenotype of gastric cancer [38].
These divergent results indicate that there might be other
factors that play a role in the regulation of the MMP-9
transcription and/or activity, such as other regulatory ele-
ments, promoter methylation or even other steps such as
secretion and type of cells under study [39,40].
The dinucleotide repeat shows a bimodal distribution
(reviewed by Van den Steen et al [15]), with the most prev-
alent allele being (CA)14 and a second peak at (CA)21–23 in
American white, Finnish, Swedish, Belgian, African-Amer-
ican and southern English population. On the other hand,
the Japanese population show the highest incidence of
(CA)21 followed by (CA)> 21. Similar to the SNP at posi-
tion (-)1562, the length of the microsatellite may influ-
ence the transcriptional activity of the gene due to its close
localization to the transcriptional start site and several
transcription factor binding sites and its length-depend-
ent interaction with nuclear proteins [31]. However, data
are inconsistent with regard to the relationship between
the length of the microsatellite and the promoter activity
[30-32]. Our analysis showed the same distribution and
that short alleles were present more frequently in patients
at higher risk for melanoma.
There are no published data on the effect of the coding
polymorphisms in the MMP-9 activity therefore; it is not
possible to hypothesize which variants could be associ-
ated with advanced stages of the disease and/or shorter
progression-free survival. In this analysis, we found that
the reference alleles were more frequent among patients
with higher risk for melanoma development (tendency to
sunburn, family history of melanoma), more advanced
disease (higher melanoma stage, presence of intransit
metastasis), and desmoplastic melanoma. However, after
adjustment for age, sex, phenotypic index, moles, and
freckles only four of these associations remained signifi-
cant. The 279QQ genotype was associated with the pres-
ence of intransit metastasis (padjusted = 0.02) and tendency
to sunburn (padjusted< 0.01); the 574R allele was more
common among patients with melanomas in the extrem-
ities (padjusted = 0.02); and 668RR was associated with the
tendency to sunburn (padjusted = 0.02). Our genotyping
results suggest that the "reference" MMP-9 enzyme is
more active than the "variant" product. These observa-
tions agree with the results of a very recent case-control
study conducted in Japanese that suggests a link between
the R279Q polymorphism and malignant potential of
renal cell carcinoma [41].
Our study subjects included ten patients who were
younger than 18 years old at diagnosis. In this particular
group, the etiology of the disease may differ from the eti-
ology of melanoma in adults. However, other than the
presence of spitzoid melanomas in 4 of 10 of these
patients, we did not find any additional withstanding
clinicopathological or genotypic characteristic and there-
fore, they were not excluded from the analysis.
Interestingly, variant alleles (-)1562T and 668Q were
more frequent among patients with primary melanomas
localized to non-cutaneous sites, mainly mucosal
melanomas (90%). Whether there is a significant associa-
tion between these SNPs and mucosal melanoma remains
to be determined in a larger group of patients with this
type of the disease.
Conclusion
We examined 437 correlations between clinicopathologi-
cal variables and 5 MMP-9 polymorphisms. Although we
found 39 statistically significant associations, after adjust-
ment, only 4 of these associations remained significant
and displayed no clear pattern, consequently the correla-
tions may simply be due to chance. Thus, we conclude
that this study does not provide strong evidence for fur-
ther investigation into the role of the MMP-9 variants in
melanoma progression.
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